CoSara and Co-Diagnostics Set to Showcase New Technology at VIROCON 2025 in Pune, India

CoSara and Co-Diagnostics to Showcase Innovations in Pune

Co-Diagnostics, Inc., a recognized player in molecular diagnostics, is set to make its presence felt at VIROCON 2025, scheduled for December 8-10, at the Conrad Hotel in Pune, Maharashtra, India. This event is significant as it provides a platform for the company to display advancements made through its joint venture, CoSara Diagnostics Pvt. Ltd.

The event marks a crucial instance for CoSara as it actively supports the second phase of preclinical studies for two key diagnostic tests: the Co-Dx PCR MTB test, aimed at detecting tuberculosis, and the Co-Dx PCR HPV multiplex test, which identifies various strains of the human papillomavirus.

The first phase of testing for the MTB test involved a comprehensive analysis of 354 clinical specimens sourced from sputum and tongue swabs, which allowed for initial assessments of sensitivity and specificity. Currently, in phase two, evaluation has progressed to 211 sputum specimens, aimed at establishing concordance with existing tests for better accuracy in identifying Mycobacterium tuberculosis.

Simultaneously, the HPV multiplex test undergone validation with 286 clinical specimens aimed at optimizing the proprietary Co-Primers® test chemistry for detecting eight distinct HPV genotypes. Phase II has introduced an additional 53 specimens to enhance the algorithm's ability to differentiate between three high-risk HPV types known to be cancer-causing.

Co-Diagnostics is optimistic about the results emerging from these preclinical studies, as they provide a robust foundation for advancing to clinical performance testing, a necessary step prior to regulatory submissions to Indian authorities. This progress reflects the company’s commitment to meeting vital health challenges through innovative diagnostic solutions.

During the VIROCON 2025 conference, attendees are welcomed to visit CoSara’s booth for in-depth discussions about their forthcoming products, including the advanced tuberculosis and HPV tests using the Co-Dx PCR platform. CoSara aims to engage with researchers and health professionals, fostering discussions that could pave the way for future collaborations.

VIROCON 2025, organized by the India Council of Medical Research - National Institute of Virology, focuses this year on the theme of 'Changing Landscape in Human, Animal, and Plant Viruses.' The conference presents an opportunity for scientific exchange and exploration of joint efforts aimed at mitigating viral threats across various domains.

Co-Diagnostics, headquartered in Utah, is dedicated to developing state-of-the-art diagnostics technologies. Their unique approach leverages a patented platform tailored for accurately detecting nucleic acids (DNA or RNA), a fundamental aspect in the realm of infectious disease diagnosis. As they prepare for this landmark event, the company continues to refine its offerings and expand its impact on public health initiatives worldwide.

In conclusion, CoSara's participation in VIROCON 2025 is not merely a showcase of technological prowess but also a testament to the growing collaboration between private enterprises and public health sectors in addressing pressing global health issues. With the aim of delivering timely and effective diagnostic solutions, Co-Diagnostics and CoSara look forward to engaging with attendees and contributing solutions that advance human health.